Published in Ann Intern Med on April 15, 1998
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol (2001) 2.79
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol (1999) 2.29
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89
Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol (2003) 1.72
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS (2010) 1.68
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol (2003) 1.62
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Innate immune recognition and activation during HIV infection. Retrovirology (2010) 1.45
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One (2010) 1.36
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS (2009) 1.35
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol (2007) 1.32
Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review. PLoS One (2009) 1.31
Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol (1998) 1.30
Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr (2009) 1.27
Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest (2002) 1.26
Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS (2009) 1.20
Alterations in brain metabolism during the first year of HIV infection. J Neurovirol (2011) 1.20
The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study. J Urban Health (2003) 1.16
Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS (2010) 1.15
HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses (2008) 1.14
Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol (2004) 1.11
Lack of evidence for changing virulence of HIV-1 in North America. PLoS One (2008) 1.11
Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening. Emerg Infect Dis (2016) 1.09
Precise determination of time to reach viral load set point after acute HIV-1 infection. J Acquir Immune Defic Syndr (2012) 1.05
Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol (2012) 1.03
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol (2004) 1.01
Identifying people with acute HIV infection: demographic features, risk factors, and use of health care among individuals with AHI in North Carolina. AIDS Behav (2009) 0.98
Nucleic acid assay system for tier II laboratories and moderately complex clinics to detect HIV in low-resource settings. J Infect Dis (2010) 0.97
Immunophenotypic alterations in acute and early HIV infection. Clin Immunol (2007) 0.94
Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy. J Leukoc Biol (2008) 0.93
Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther (2014) 0.90
Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants. Vaccine (2009) 0.88
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One (2013) 0.87
Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group. Int J STD AIDS (2012) 0.87
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis (2010) 0.85
A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One (2010) 0.85
Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication. J Virol (2013) 0.85
Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0. Clin Diagn Lab Immunol (2001) 0.84
Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques. J Virol (1999) 0.84
An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load. PLoS Comput Biol (2014) 0.84
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis (2010) 0.83
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Evaluation of the quantiplex human immunodeficiency virus type 1 RNA 3.0 assay in a tertiary-care center. Clin Diagn Lab Immunol (2000) 0.81
In utero and intra-partum HIV-1 transmission and acute HIV-1 infection during pregnancy: using the BED capture enzyme-immunoassay as a surrogate marker for acute infection. Int J Epidemiol (2011) 0.80
Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help? Curr Opin HIV AIDS (2015) 0.80
Effect of hormonal contraceptive use before HIV seroconversion on viral load setpoint among women in Rakai, Uganda. J Acquir Immune Defic Syndr (2011) 0.79
Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy. PLoS One (2013) 0.79
Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure. AIDS Res Hum Retroviruses (2012) 0.78
Recent HIV-1 infection: identification of individuals with high viral load setpoint in a voluntary counselling and testing centre in rural Mozambique. PLoS One (2012) 0.77
Neurobehavioral Disturbances During Acute and Early HIV Infection. Cogn Behav Neurol (2016) 0.77
Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. J Virol (2015) 0.76
Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection. Viruses (2012) 0.76
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr (2011) 0.76
A conceptual model of interventions to increase diagnosis of acute HIV infection and reduce forward transmission. AIDS Behav (2011) 0.76
HIV elimination and population viral load. Lancet HIV (2016) 0.75
Characteristics of primary HIV infection. Ann Intern Med (1999) 0.75
Low CD1c + myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection. BMC Infect Dis (2015) 0.75
Diversity of trends of viremia and T-cell markers in experimental acute feline immunodeficiency virus infection. PLoS One (2013) 0.75
Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects. BMC Immunol (2016) 0.75
The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion. AIDS (2017) 0.75
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med (1996) 4.69
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol (1981) 4.10
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med (1993) 3.51
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med (1980) 3.33
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med (1981) 3.32
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Effects of electronic fetal-heart-rate monitoring, as compared with periodic auscultation, on the neurologic development of premature infants. N Engl J Med (1990) 3.04
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry (1992) 2.84
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Sexual mixing patterns of patients attending sexually transmitted diseases clinics. Sex Transm Dis (1996) 2.76
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med (1987) 2.74
Sexually transmitted diseases in victims of rape. N Engl J Med (1990) 2.74
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis (1983) 2.60
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Chronic fatigue. A prospective clinical and virologic study. JAMA (1990) 2.54
Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health (1999) 2.54
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
Typing of clinical herpes simplex virus isolates with mouse monoclonal antibodies to herpes simplex virus types 1 and 2: comparison with type-specific rabbit antisera and restriction endonuclease analysis of viral DNA. J Clin Microbiol (1983) 2.50
Logistic regression when the outcome is measured with uncertainty. Am J Epidemiol (1997) 2.49
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) J Neuropathol Exp Neurol (1994) 2.34
Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med (1983) 2.33
Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med (1990) 2.32
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med (1985) 2.23
Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol (1988) 2.22
Infections with herpes simplex viruses (2). N Engl J Med (1986) 2.22
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol (1992) 2.19
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med (1991) 2.12
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis (1999) 2.07
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis (1991) 2.06
Perforation of the bladder: a complication of long-dwelling Foley catheter. J Urol (1973) 2.05
Epidemiology of Reye syndrome. Epidemiol Rev (1981) 2.04